Fate Therapeutics: Q1 Earnings Snapshot

Published: 2025-05-13 16:14:16 ET FATE

Published on 05/13/2025 at 16:14

SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Tuesday reported a loss of $37.6 million in its first quarter.

On a per-share basis, the San Diego-based company said it had a loss of 32 cents.

The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.

The clinical-stage biotech company that develops stem cell treatments posted revenue of $1.6 million in the period.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News